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Abstract
Purpose The purpose of the study was to develop a drug-
unspecific approach to pharmacometric modeling for
predicting the rate and extent of distribution from plasma to
epithelial lining fluid (ELF) and alveolar cells (AC) for data
emanating from studies involving bronchoalveolar lavage
(BAL) sampling, using rifampicin (RIF) as an example.
Methods Data consisting of RIF plasma concentrations sam-
pled at approximately 2 and 4 h postdose and ELF and AC
concentrations quantified from one BAL sample, taken at
approximately 4 h postdose, in 40 adult subjects without
tuberculosis was used as an example for model development.
Results This study emphasized the usage of drug-specific
plasma pharmacokinetics (PK) for a correct characterization
of plasma to pulmonary distribution. As such, RIF PK was
described using absorption transit compartments and a one
compartment distribution model coupled with an enzyme
turn-over model. The ELF and AC distribution model
consisted of characterization of the rate of distribution of drug
from plasma to ELF and AC by two distribution rate constant,
kELF and kAC, respectively. The extent of distribution to ELF
and AC was described by unbound ELF/plasma concentration
ratio (RELF/unbound-plasma) and unbound AC/plasma concentra-
tion ratio (RAC/unbound-plasma) which typical values were pre-
dicted to be 1.28 and 5.5, respectively.
Conclusions The model together with a drug-specific plasma
PK description provides a tool for handling data from both
single and multiple BAL sampling designs and directly pre-
dicts the rate and extent of distribution from plasma to ELF
and AC. The model can be further used to investigate design
aspects of optimized BAL studies.
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Introduction
Pulmonary distribution is of high interest in the field of
antituberculosis drugs. Even though tuberculosis is not a
lung-exclusive disease, and can affect various organs and
tissues, pulmonary tuberculosis is the most common and
perhaps most recognized form of the disease. Many of the
first-line drugs today used in treatment of pulmonary tuber-
culosis were launched in the 1950s and 1960s, and natural-
ly, little was then known about the rate and extent of
pulmonary penetration and the correlation between plasma
concentrations and concentrations at the site of action.
Today tuberculosis is still a major and global health prob-
lem, ranked as the second leading cause of death from an
infectious disease worldwide [1]. The development of new
antibiotics is not matching the incline in resistance against
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the available antibiotics today. To illustrate, the approval of
bedaquiline by the FDA marked the first new antitubercular
agent approved in over 40 years and this for a disease that in
2012 alone was estimated to have been developed in 8.6
million people worldwide [1].
An example of a problem potentially emanating from the
lack of integration of pharmacokinetic (PK) and pharmaco-
dynamic (PD) analysis in drug development for drugs
launched in the 1950s and 1960s is the today widely rec-
ognized suboptimal dosing of rifampicin (RIF) [2, 3]. RIF
is one of four drugs that make up the current first-line
antituberculosis drug therapy for treatment-naïve adults
recommended by the world health organization (WHO).
The PK of RIF is well characterized in plasma [4, 5] and
with the possibility brought by new methods and tech-
niques, there today exists a number of publications
reporting drug concentrations quantified from samples tak-
en from the pulmonary tract both for RIF [6, 7] and review
articles for antimicrobials in general [8, 9]. Despite this, for
many drugs, the effects of active transporters, disease-
afflicted tissue, and the differences in the efferent of sam-
pling and quantification methods are still to some extent
uncharacterized and not well understood. Shedding new
and more light on these still unclear areas is an important
part of the research focused on finding and describing the
important relationship between PK and PD, such as clinical
and microbiological outcomes.
Bronchoalveolar lavage (BAL) is used in both drug research
and in clinical practice as a way to quantify drug concentrations
from epithelial lining fluid (ELF) [6, 10] and alveolar cells (AC)
[6, 11]. Information about the extent of distribution, often
parameterized as ELF/plasma and AC/plasma concentration
ratios, is of great value in order to assess whether sufficient
drug concentrations are achieved at extracellular (ELF) and
intracellular (AC) sites. The volumes of cells in ELF has been
reported to consist of 83 % macrophages, 17 % lymphocytes,
and 1 % neutrophils [9] making quantified AC concentrations
mainly reflect the concentrations in macrophages. However, it
is not only the extent of distribution to the lung that is of
importance. Capturing the rate of distribution from plasma to
the lung is important when obtaining relationships between PK
and PD. This is especially relevant for drugs and compounds
without an instantaneous or fast equilibrium between plasma
and the lung, where the exposure in plasma may not be a good
marker of the drug exposure at the site of action and could
potentially distort PKPD relationships.
Obviously, there is a need for more innovative approaches
and high quality research targeting both existing treatments as
well as novel antitubercular drugs. The aim of the present
work was hence to develop a general pharmacometric pulmo-
nary model for predicting the extent and rate of drug distribu-
tion from plasma to ELF and AC using RIF as an example.
Such a model will have the potential to increase knowledge
about distribution and PKPD properties of existing drugs as




Data from a previously published study [6] were used in this
pharmacometric analysis. Written informed consent, according
to the guidelines of the Institutional Review Board of The
University of California, San Francisco, USA, was obtained.
The study consisted of 40 adult subjects without tuberculosis
and included 10 women without acquired immunodeficiency
syndrome (AIDS), 10 men without AIDS, 10 women with
AIDS, and 10 men with AIDS. The subjects received 600 mg
RIF orally once a day for 5 days. Rifampicin plasma concen-
trations were measured on day 5 at approximately 2 and 4 h
postdose. Rifampicin concentrations in ELF and AC recovered
by BAL were measured at approximately 4 h after administra-
tion of the last dose. Rifampicin concentrations were measured
by high-performance liquid chromatography [12]. For the de-
termination of the RIF concentrations in ELF and AC, the
volume of the ELF recovered by BAL was calculated by using
the urea dilution method [13], while the volume of AC was
estimated from the cell count performed in BAL fluid [6].
Pharmacokinetic modeling and model evaluation
Data analysis was performed using the software NONMEM,
version 7.2 (ICON Development Solutions, Ellicott City,
USA) [14], using the first order conditional estimationmethod
with interaction (FOCE INTER). R (version 3.0.1) [15] was
used for graphical analysis and data management. PsN 3.6.9
[16–18] was used for prediction-corrected visual predictive
checks (pcVPC). Xpose (version 4.4.1) [19] was used for
visualization of data and results. Numerical model comparison
and a run record was utilized and maintainedwith the software
Pirana (version 2.7) [20].
A total of 76 plasma, 32 ELF, and 36 AC concentrations
were included in the analysis. The model building process was
performed in a stepwise fashion, starting from the previously
published RIF PK enzyme turn-over model in order to account
for RIF autoinduction [5]. The model consisted of a one
compartment disposition model with absorption transit com-
partments. The mean transit time (MTT) and the number of
transit compartments (N) were fixed to previously published
values [5] due to insufficient sampling in the absorption phase.
RIF plasma concentrations increased the enzyme production
rate (kENZ), which in turn increased the enzyme pool in a non-
linear fashion by means of an EMAX-model. The parameters
related to the autoinduction of RIF oral clearance (CL/F) were
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also fixed to the previously published values [5], as the data
contained only 5 days of treatment, and as such only limited
information about the time to steady-state (approximately
40 days) [5] was available. The impact of allometric scaling
was assessed by using four different basic turn-over models:
(1) no scaling, (2) allometric scaling using bodyweight as the
size descriptor, (3) allometric scaling using normal fat mass
(NFM) as the size descriptor, and (4) allometric scaling using
fat free mass (FFM) as the size descriptor. The typical value
(TV) of CL/F and apparent central volume of distribution (Vc/
F) were scaled allometrically standardized to each of the size


























where MASSi denotes individual values of the three size de-
scriptors, bodyweight, NFM, and FFM used in the respective
basic models. (CL/F)STD is the typical oral clearance at pre-
induced state in a patient weighing 70 kg and (Vc/F)STD is the
typical volume of distribution in a patient weighing 70 kg.
Individual FFM values (FFMi) were calculated as:
FFMi ¼ WHSMAX  HT
2 WT
WHS50  HT2 þWT
ð3Þ
where the maximal weight height squared (WHSMAX) is
42.92 kg/m2 and WHS50 is 30.93 kg/m
2 in men. WHSMAX
is 37.99 kg/m2 and WHS50 is 35.98 kg/m
2 in women. HT is
height in meters. NFMwas expressed differently forCL/F and
V/F as described by Andersson and Holford [21]:
NFMi ¼ FFMi þ Ffatð ÞCL
F
 WTi − FFMið Þ ð4Þ
NFMi ¼ FFMi þ Ffatð ÞV
F





denote the estimated contribution
of fat mass to CLF and
V
F, respectively.


















where C is concentration, kELF and kAC are the rate constants
for the transfer of drug from the plasma to ELF or AC,
respectively. RELF/plasma and RAC/plasma are the ELF/plasma
and AC/plasma concentration ratios, respectively, at pseudo
steady-state. Aplasma/Vplasma is the concentration of drug pre-
dicted in the plasma compartment at time t, with Aplasma being
the amount of drug in plasma and Vplasma being the apparent
plasma volume of distribution. To derive the ratio of ELF and
AC to unbound plasma concentrations, (RELF/unbound-plasma)
and (RAC/unbound-plasma), respectively, RELF/plasma, and RAC/plas-
ma were divided by free fraction of RIF in plasma (0.2) [23].
The protein concentration in ELF has previously been report-
ed to be between 3.9 and 8 mg/ml, depending on disease state,
representing only 6–12 % of the plasma concentration for
children with and without congestive heart disorder [24]. In
a similar study with healthy infants, similar results were
reported with regards to protein concentration in ELF, 3.3–
4.6 mg/ml depending on sampling technique [25]. The exact
protein binding will naturally vary with different populations
but based on the low concentration reported for children and
lacking a more relevant value for this population, the protein
binding in ELF and ACwas judged to be negligible and hence
not taken into account.
The likelihood ratio test (LRT) was used to evaluate statis-
tical significance for inclusion of additional parameters in
nested models, where the objective function value (OFV) is
assumed to be χ2 distributed. A decrease in the OFVof 3.84
points between hierarchical models with one parameter dif-
fering was considered as a statistical difference at the 5 %
significance level. Model selection was guided by goodness-
of-fit plots, pcVPCs, parameter precision, and scientific
plausibility.
Results
A schematic representation of the final pharmacometric pul-
monary model is shown in Fig. 1.
The final model included allometric scaling using FFM.
This model had 22 points lower OFV compared to a model
without scaling. Models with allometric scaling using NFM
and bodyweight had an OFV drop of 22 and 18, respectively,
compared to the model without scaling. Scalingwith FFM and
NFM had the same OFV value. However, the former was
selected due to fewer parameters compared to a model with
NFM scaling.
To mimic an almost instantaneous distribution from
plasma to the lungs, the rate constants for the transfer
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of drug from the plasma to ELF or AC, kELF and kAC,
respectively, were fixed to an equivalent of an equili-
bration half-life of about 1 min (instantaneous). This
was needed as the sample design included only one
sample per subject that was taken approximately at the
same time (4 h) in all subjects wherefore the rate of
distribution could not be estimated. The sampling time
point of 4 h was also judged to occur when distribution
equilibrium had been reached between plasma, ELF, and
AC. Since the lung is a highly perfused organ and that
this assumption of the rate of distribution does not
affect the estimate of the extent of distribution, the
assumption is valid for estimation of the extent of
distribution at 4 h.
The final model predicted the plasma, AC, and ELF data
well (Fig. 2). The parameter estimates of the final model are
shown in Table 1. The RELF/plasma and RAC/plasma were predict-
ed to be 0.26 and 1.1, respectively. When adjusting for free
fraction of 20 % in plasma [23], the unbound RELF/unbound-
plasma and RAC/unbound-plasma ratios were predicted to be 1.28
and 5.5, respectively. Interestingly, when the RELF/plasma and
RAC/plasma were not corrected for unbound fraction in plasma,
the model predicted the exposure in ELF to be lower than in
plasma whereas the reverse was seen when accounting for the
protein binding in plasma.
Discussion
The semi-invasive nature of the BAL technique makes repeat-
ed sampling from the same subject more problematic than
compared to repeated sampling using a non-invasive method.
This leads to that many studies involving BAL sampling has
only one or a few samples per subject available to quantify the
distribution of the drug from plasma to ELF and AC. This
poses a problem as a traditional pharmacokinetic compart-
ment model approach for plasma as well as lung observation
often involves describing the distribution of drug over time.
When as in this case a one sample per subject design have
been utilized, the traditional compartmental approach, unless
all subjects are sampled at very different time points, will not
be able to quantify the compartmental model parameters with
a high accuracy or precision. Well aware of this limitation and
potential lack of available tools to handle such data, we have
developed a general pharmacometric pulmonary model that,
together with a substance-specific plasma PK model, can be
used with both one sample per subject as well as more rich
BAL sampling designs focusing on characterizing the con-
centration ratios between ELF/plasma and AC/plasma instead
of the distribution of drug over time. The concentration ratios
are measurement of the extent of distribution which is, in this
pharmacometric pulmonary model, directly obtained with
parameter precision. In addition, the rate of distribution can
be quantified using an optimized sampling design or fixed to
instantaneous distribution if samples are only taken as in this
design at one late time point resembling a pseudo steady-state.
In such situation, only the extent of distribution will be quan-
tified which was the situation in this example where rifampi-
cin were sampled in ELF and AC at 4 h postdose. In this
analysis example, no IIV was quantified for the parameters
describing the rate or extent of distribution. In order to allow
for IIV to be quantified with good precision, more than one
sample per subject is needed.
Our suggested approach is not drug specific and can be
applied to any drug as long as the plasma PK submodel is
optimized for the particular drug. When assessing the distri-
bution of drug from as in this case plasma to pulmonary tissue,
it is not only important to in a correct way describe the
pulmonary distribution but also strive to as correctly as pos-
sible describe the plasma PK properties of the drug. Failure of
capturing the plasma PK properties of the drug will not only
bias the description of the plasma concentrations of the drug
but also the relationship of drug concentrations in plasma and
the pulmonary tract. It is thus equally important to develop an
as true as possible plasma PK submodel as the submodels
relating to the pulmonary concentrations. The plasma PK
submodel in this work was based on a previously published
RIF pharmacometric model that included auto induction [5].
Without inclusion of the enzyme component in the plasma PK
submodel that accounts for the autoinduction, the description
Fig. 1 Schematic representation of the final rifampicin (RIF) lung and
plasma pharmacometric submodels. Drug is transferred via a number of
transit absorption compartments to the absorption compartment and
further via the rate constant ka to the central plasma compartment. Rifam-
picin autoinduction was modeled with an enzyme turn-over model in
which the RIF plasma concentrations increased the enzyme production
rate (kENZ) which in turn increased the enzyme pool in a non-linear
fashion by means of an EMAX-model. Cp is the RIF plasma concentration
and Emax is the maximal autodinduction of CL/F. EC50 is the RIF
concentration resulting in 50 % of the maximal autoinduction of CL/F.
The ELF and AC drug penetration sub models were described using two
parameters for each submodel. The rate of distribution of drug from
plasma to ELF and AC was captured by two distribution rate constant,
kELF and kAC, respectively. The extent of distribution to ELF and ACwas
described by unbound ELF/plasma concentration ratio (RELF/unbound-plas-
ma) and unbound AC/plasma concentration ratio (RAC/unbound-plasma)
316 Eur J Clin Pharmacol (2015) 71:313–319
of the plasma to ELF and AC concentration ratios would have
been biased. As with all analysis involving the use of previ-
ously published approaches, estimations using the new study
population where performed where possible. As the data used
in this analysis were sparse and only included two plasma
samples per subject, estimation of all parameters were not
possible. These parameters where then fixed to the values
reported by the authors of the original publication [5]. Evalu-
ation of allometric scaling of CL/F and V/F with bodyweight,
FFM, and NFM resulted in similar OFVs for the models using
NFM and the FFM size descriptor and a higher OFV value
using scaling with bodyweight. The FFM scaling method was
judged superior based on the two extra parameters required by
the NFM method.
The dataset used for model development included 40 sub-
jects with ELF and AC concentrations quantified from one
BAL sample per subject. In addition to the sparseness of the
data, the difference in interindividual sampling times was very
small. In the estimation of the unbound concentration ratios
RELF/plasma and RAC/plasma, two assumptions regarding protein
binding weremade. The concentration ratios were adjusted for
protein binding based on that only the free fraction of a drug is
able to distribute from blood to the interstitial fluid and that
this unbound drug concentration is believed to be more close-
ly associated to drug efficacy. In the model, no adjustment was
made for protein binding in ELF or AC. The protein levels in
ELF have previously been shown to be low and even though
potentially present, the effect from it was judged to be negli-
gible, wherefore most likely the total and the unbound con-
centrations of drugs in ELF are similar [9]. No information
was available regarding the protein binding in AC, and it was
therefore assumed to be negligible as in ELF. The parameters
RELF/plasma and RAC/plasma in the model represent the concen-
tration ratios of RIF from ELF and AC to plasma. The final
model estimated RELF/unbound-plasma and RAC/unbound-plasma to
be 1.28 [coefficient of variation (CV)=10 %] and 5.5 (CV=
9 %), respectively. The model predicted the unbound concen-
tration in ELF and AC to be higher than in plasma since the
unbound ratio was predicted to be greater than 1. Interestingly,
if protein binding was not accounted for, the total concentra-
tion ratios of ELF and AC in relation to plasma were 0.26 and
1.1, respectively. As such, without accounting for the protein
binding, the model predicted lower ELF concentrations
Table 1 Parameter estimates and relative standard errors of the final
model
Parameter Estimate (95 % CI) Relative standard
error (%)
TV(CL/F)STD (L h
−1) 3.85 (2.26–8.68) 3.1
















RAC/plasma 1.1 (0.92–1.35) 6.2
RAC/unbound-plasma 5.5
c
IIVCL/F (%) 88.8 (9.43–106.77) 24.2
Plasma proportional error (%) 35.2 (25.11–45.42) 3.6
ELF proportional error (%) 40.7 (30.26–54.76) 2.9
AC proportional error (%) 37.1 (22.95–46.91) 7.3
IIV interindividual variability expressed as coefficient of variation, RSE
relative standard error reported on the approximate standard deviation
scale
a Fixed parameter
b Calculated post estimation as RELF/plasma divided by the free fraction in
plasma (20 %) [23]
c Calculated post estimation as RAC/plasma divided by the free fraction in
plasma (20 %) [23]
Fig. 2 Prediction-corrected visual predictive check of the final RIF
plasma, ELF and AC pharmacometric submodels. The open circles are
the population prediction-corrected observations. The solid line is the
median of the observed data and the dashed lines are the 5th and 95th
percentiles of the observed data. The top and bottom shaded areas are the
95 % confidence intervals for the 5th percentile and the 95th percentile of
simulated data. The middle shaded area is the 95 % confidence interval
for the median of the simulated data
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compared to plasma although the reverse was seen using the
unbound ratio.
As reported by others, there are a number of factors that
could have unwanted and in some cases undistinguishable
influence over the results originating from studies using
BAL [8]. The perhaps simplest example being that the efferent
of the BAL method varies between studies, hence making the
results to some extent incomparable [8]. Another source of
error is the risk of contamination of ELF concentrations from
lysis of the components that make up the ELF mixture. For
example, lysis of alveolar macrophages could potentially lead
to an artificially increased antibiotic concentration measured
in ELF [9]. Despite the shortcomings mentioned above, the
BAL method enables a relative simple way of sampling ELF
from the surface of the alveolar wall and further quantification
of drug concentrations in ELF and AC [8].
The possibility to sample and quantify drug concentrations
close to the site of effect in the lung is of interest for pulmo-
nary infections as the concentrations of antibiotics in ELF for
extracellular pathogens and in AC, especially in macrophages,
for intracellular pathogens, are thought to reflect antibiotic
activity in pneumonia [9]. The concentration ratios estimated
by our model describe the extent of distribution and are a good
indication of the studied drug’s potential to reach the site of
action and have effect at extracellular and intracellular sites in
the lung. The rate of distribution to ELF and AC from plasma
was in the model captured by the rate constants kELF and kAC.
However, due to the sparseness of information in the data
where only one sample was obtained in the subjects at a time
point when equilibrium of distribution from plasma to the
lung had occurred (4 h), the rate of distribution could not be
estimated but instead an instantaneous distribution from plas-
ma to ELF and AC was assumed. Although this study design
allowed for estimation of the extent of distribution, the true
rate of distribution could have been obtained using a more
informative sampling design. Capturing the rate of distribu-
tion from plasma to the site of action is of great interest as it
dictates if plasma is a good predictor of a PKPD relationship
or not for a particular drug. If the rate of distribution is fast, the
ratio of drug concentrations at the site of action and in plasma
will quickly become constant. Plasma PK would in such a
situation be a good marker of PK at the site of action, and it
would be possible to relate concentrations in plasma
(exposure) to the effect when obtaining PKPD relationships.
However, in the case of a slow rate of distribution, the rela-
tionship between plasma concentrations and effect would be
less relevant as the effect is governed by a concentration at the
site of action which would not be directly reflected by plasma
concentrations. The failure of realizing this could potentially
lead to suboptimal dosing causing treatment failure and higher
risk of emergence of bacterial drug resistance.
The final pharmacometric pulmonary model described RIF
plasma PK including autoinduction, with the use of an enzyme
turn-over model, and the distribution of RIF from plasma to
ELF and AC. Our results are in agreement with previously
reported results with regards to RIF’s general pharmacokinetic
properties [4, 5, 26]. Typical oral clearance and volume of
distribution were estimated to be 3.8 and 76.6 L, respectively.
The influence of potential subpopulation-specific properties or
covariates where not explored in this analysis. The effect of
covariates specific to RIF and this specific population have
been explored in a previous publication [6].
In summary, a pharmacometric pulmonary model was de-
veloped for quantifying the extent and rate of distribution
from plasma to ELF and AC to be used for single or multiple
sample designs. Quantification of the rate of distribution to
ELF and ACwill, in comparison to the PK in plasma, define if
plasma is a good marker for drug exposure at the site of action
or if PKPD relationships should be built using pulmonary PK.
Information about the extent of distribution to ELF and AC
will provide information about the expected drug exposure in
lung. The ELF and AC submodels are not drug dependent and
can as such be applied to other drugs where drug exposure in
the lung is of interest. The model can also be used for further
investigations of optimized BAL sampling designs.
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